REGN
$816.10+1.04%
as of close, Oct 27, 2026
☾ AH $816.10 +1.04%
REGN — Regeneron Pharmaceuticals Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEEEEEEEEEEEEEDEDEDEDEDEDED
300.0400.0500.0600.0700.0800.0900.01000.01100.0010.0M$816.10—20162019202120242026
2026-10-27
Price$816.10
MA20$723.35
MA50$712.62
Vol2.5M
Key stats#
Price data
- Price
- $816.10
- YTD price return
- +5.73%
- YTD total return
- +6.14%
- Next earnings
- Oct 30, 2026 · Before open
- Market cap
- 84B
- Enterprise value
- 79B
- Shares outstanding
- 103M
- 52W low
- $575.93
- 52W high
- $859.34
- From 52W high
- -5.03%
- From 52W low
- +41.70%
- 52W range
- 85%
- Beta
- 0.20
Volume
- Rel volume
- 0.98×
- 30D volume
- 731.9K
- 30D $ vol
- 567.9M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$3.2M
- Insider net 3M
- −$6.5M
- Insider net 1Y
- −$11.0M
Form 4 transactions by trade date, as filed; latest on file 2026-10-14.
Fundamentals
- Sales (ttm)
- 15.5B
- Sales/share
- $150.89
- EPS (ttm)
- $40.40
- FCF (ttm)
- 3.8B
- FCF/share
- $36.52
- Book value/share
- $308.01
- Net margin
- 27.86%
- ROE
- 13.65%
- ROA
- 10.37%
- Debt / equity
- 0.06×
- Current ratio
- 3.34
Growth (CAGR, ttm) · 10Y
- Sales
- +9.30%+7.03%+4.64%+12.82%
- Net income
- -2.92%+0.23%-6.95%+19.27%
- FCF
- -2.42%-3.25%+17.30%+13.58%
- Shares
- -2.86%-1.75%-0.76%-1.21%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +1.84%+2.23%-6.22%+20.16%
- Sales/share
- +12.52%+8.93%+5.44%+14.20%
- FCF/share
- +0.45%-1.53%+18.20%+14.97%
- Book value/share
- +9.05%+11.66%+16.85%+24.27%
- Dividend/share
- +119.61%n/an/an/a
- Price
- +39.46%+1.73%+6.72%+8.43%
- Total return
- +40.18%+2.05%+6.92%+8.54%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 20.2×
- P/OI (ttm)
- 21.9×
- Fwd P/E
- 12.8×
- P/S (ttm)
- 5.4×
- P/B (mrq)
- 2.6×
- P/FCF (ttm)
- 22.3×
- EV/EBITDA (fy)
- 18.1×
- EV/Sales (ttm)
- 5.1×
- FCF yield (ttm)
- 4.48%
- Dividend yield (fwd)
- 0.46%
- Dividend yield (ttm)
- 0.45%
- Dividend/share (fwd)
- $3.76
- Buyback yield (realized, 1y)
- 2.86%
- Shareholder yield (realized, 1y)
- 3.54%
- Buyback yield (cash, ttm)
- 3.03%
- Shareholder yield (cash, ttm)
- 3.48%
Vs own 10Y history
- P/E
- 55th
- P/OI
- 70th
- P/S
- 30th
- P/B
- 17th
- P/FCF
- 47th
Bar = where today’s multiple sits in REGN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+1.04%
5D
+1.07%
1M
+3.56%
3M
+22.32%
YTD
+5.73%
1Y
+39.43%
5Y
+38.42%
Recent filings#
- Oct 68-K · Material definitive agreement; Results of operations; Other events
- Jul 30Earnings · Earnings release — EPS $12.53 vs $8.00 est. (+56.6%); revenue $4.29B (+17% y/y) 6.2%
- Jul 68-K · Results of operations
Financial statements
Open full REGN financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
